Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.50 (-3.51%)
Spread: 0.50 (3.704%)
Open: 14.25
High: 14.25
Low: 13.75
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic Partnership

27 Jul 2006 07:00

Angle PLC27 July 2006 For Immediate Release 27 July 2006 ANGLE plc ('ANGLE' or 'the Company') 20 year strategic partnership with The University of Reading ANGLE plc ('ANGLE'), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce that it hassigned a 20 year strategic partnership with The University of Reading ('University'). Under the terms of the agreement, ANGLE has the exclusive right of first refusalto invest in all University intellectual property (IP) that is commercialised.Where ANGLE exercises this right, it will invest under a set formula obtainingan equity stake of 60% in each spin-out company for an investment of up to £0.5million. ANGLE will drive development of these ventures utilising itsproprietary Progeny(R) process. Additionally, ANGLE will receive a 15% share in all commercial returns fromUniversity IP, both licensing and spin-out, in which ANGLE does not invest. Inexchange, ANGLE will provide consultancy support to the University on IPcommercialisation. In total, ANGLE expects to invest at least £3.0 million over the first fiveyears of the agreement and expects that this will be funded from existingresources. The University has income of more than £150 million per annum and over 1,000academic staff. The most recent government Research Assessment Exercise ratedtwenty of its departments as 5 or 5*, denoting international excellence inresearch activity. This excellence is found in areas as diverse as climatephysics, fluid dynamics and food biosciences, the latter of which is ideallyplaced as the global market for functional foods grows towards an estimated $95billion per annum by 2010. In addition, the University's Instrumentation &Signal Processing Research Group and Cybernetic Intelligence Research Group bothpossess not only high international reputations but also strong histories ofproducing groundbreaking, commercial technologies. ANGLE is already workingwith the University to evaluate opportunities arising from these and otherareas. The University has a long tradition of being at the forefront of commercialactivities, as the first British university to integrate an industrial R&D groupon its campus; the first university to win the Queen's Award for ExportAchievement; the host to the UK's leading Knowledge Transfer Partnership (KTP)Centre; the provider of one of the largest credit bearing entrepreneurshipteaching programmes in the UK; and the home of InnovationWorks@Reading, afacility for creative problem solving unique in the South East. Existingspin-out companies include Whitfield Solar, a developer of low-cost solar powersolutions that has recently joined the Carbon Trust's Incubator managed byANGLE. ANGLE's Director of New Ventures, Stephen Bence, said: "The University of Reading is a top rated research University with strength indepth through its technology base. We are delighted to have the opportunity towork with the University to commercialise its intellectual property over anextended period of time and look forward to some early successes." ANGLE's Group Chief Executive, Andrew Newland, added: "We are delighted to sign The University of Reading as ANGLE's first UKstrategic partnership. Establishing long-term relationships with owners ofimpressive intellectual property represents a new phase in ANGLE's strategicdevelopment. This ground-breaking deal is the first of a number of such dealsthat we expect to be able to announce over the next 18 months." David Savage, Director of Finance and Corporate Services at The University ofReading, said: "We have been approached by a number of IP commercialisation groups interestedin investing in the University's intellectual property but ANGLE offered aunique combination of consultancy expertise in identifying opportunities andproactive management of their development. We are confident that this strategicpartnership will deliver a step change in technology transfer from TheUniversity of Reading for the benefit of the UK economy." The University's Technology Transfer Manager, Sue O'Hare, added: "ANGLE's track record of successful spin-out companies and network ofexperienced and well-connected people are impressive. We are very excited by theopportunity to work closely with them to realise the potential of theUniversity's intellectual property and to maintain and develop the University'srecord of being at the leading edge." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures The University of Reading +44 118 935 7198Sue O'Hare, Technology Transfer Manager Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com About The University of Reading The University of Reading is one of the top 20 research-intensive universitiesin the UK, with a world-wide reputation in the areas of environmentaltechnologies, agriculture, food biosciences, information and communicationstechnologies, construction management, and financial markets. The University iscommitted to achieving excellence in research, teaching and enterprise and totranslating its excellence into a major contribution to culture, economicwell-being and the quality of life. For more information, visit www.reading.ac.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSIssue of Equity
30th Sep 20225:30 pmRNSHolding(s) in Company
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.